DV
Dividend Vision

BOLD Stock — Boundless Bio, Inc. Common Stock

Boundless Bio, Inc. Common Stock (BOLD)

Updated November 13, 2026.

BOLD is a stock. Total return is -82.5% over the past 2.6 years, 131.0 points behind SPY at 48.5%.

Boundless Bio is a clinical-stage oncology company developing therapies that target extrachromosomal DNA to treat cancers with oncogene amplification, including breast cancer subtypes. The company does not currently distribute to shareholders. This security appeals to investors with high risk tolerance seeking exposure to early-stage biotech development, as the company's lead candidate remains in Phase 1/2 clinical trials with no approved products or revenue.

BOLD performance versus SPY

Total return is -82.5% over the past 2.6 years, 131.0 points behind SPY at 48.5%. Over the past year its total return — price change plus distributions reinvested — is 108.3%. Its deepest 1-year drawdown was 23.0%.

WindowTotal returnCAGR
1M2.9%—
3M-9.9%—
6M62.3%—
YTD108.3%—
1Y108.3%—
2Y CAGR—-16.30%
Since inception 2024-03-28 · 2.6 years-82.5%-48.40%

BOLD key facts

Asset type
Stock
Asset class
Equity
Inception date
03/28/2024
Distribution frequency
None
Last close
$2.50 (as of 2026-11-13)
Market cap
$59,028,515
Average volume
156,469
Beta
0.458
Payout ratio
0.0%
EPS
-$2.49

How Dividend Vision calculates returns

Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BOLD risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 23.0%.

Who may consider BOLD — and who may not

It is a weaker fit for investors who need monthly cash flow (BOLD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BOLD

Tagged: Healthcare.

Frequently asked questions

Does BOLD pay monthly?

No. BOLD does not currently distribute.

When does BOLD pay a dividend?

BOLD does not currently distribute.

How has BOLD performed?

Total return is -82.5% over the past 2.6 years, 131.0 points behind SPY at 48.5%. Over the past year its total return — price change plus distributions reinvested — is 108.3%. Its deepest 1-year drawdown was 23.0%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.